首页> 外文OA文献 >Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

【2h】

Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

机译：具有表达FGFR2 - 融合或FGFR2突变/扩增的肝内胆管癌（ICCA）患者（DZB）在患者（PTS）中的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M. Droz Dit Busset; S. Braun; B. El-Rayes; W.P. Harris; N. Damjanov; G. Masi; L. Rimassa; S. Bhoori; M. Niger; N. Personeni; F. Braiteh; S. Lonardi; M. Engelhardt; M. Saulay; B. Schwartz; W.L. Shaib; V. Mazzaferro; K.P. Papadopoulos;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Diverse Landscape of Fibroblast Growth Factor Receptor 2 (FGFR2) Rearrangement Partners in Intrahepatic Cholangiocarcinoma (iCCA) [J] . Silverman I. M., Reeser J. W., Wing M. R., The Journal of molecular diagnostics: JMD . 2019,第6期

机译：成纤维细胞生长因子受体2（FGFR2）肝内胆管癌重排伴侣的多样化景观（ICCA）
2. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma [J] . Daniela Sia, Bojan Losic, Agrin Moeini, Nature Communications . 2015,第1期

机译：大规模并行测序发现可行的 FGFR2 – PPHLN1 融合和 <肝内胆管癌的named-entity> ARAF 突变
3. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population [J] . Xiao-Hong Pu, Qing Ye, Jun Yang, Human Pathology . 2018,第期

机译：低级克隆FGFR2扩增定义了中国人口中肝内胆管癌的独特分子亚型
4. Study on immunogenicity and protective efficacy of a new vaccine expressing Ag85B and MPT83 fusion protein from Mycobacterium tuberculosis [C] . Yufei Jin, Hong Bao, Jing Chang, International Conference on Human Health and Medical Engineering. . 2014

机译：从结核分枝杆菌中表达AG85B和MPT83融合蛋白的新疫苗免疫原性和保护效果的研究
5. Transgenic mice expressing MAPT mutations as experimental models of frontotemporal dementia and parkinsonism linked to chromosome 17. [D] . Gnezda, Anita Genie. 2006

机译：表达MAPT突变的转基因小鼠为额颞叶痴呆和帕金森氏症的实验模型，与17号染色体相关。
6. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma [O] . Vincenzo Mazzaferro, Bassel F. El-Rayes, Michele Droz dit Busset, 2019

机译：Derazantinib（ARQ 087）用于晚期或无法手术的FGFR2基因融合阳性肝内胆管癌
7. 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2 [O] . J. Furuse, L. Goyal, F. Meric-Bernstam, 2020

机译：116Mo患者（PTS）与胎儿胆管癌（ICCA）与FGFR2融合/重排的诊所（PTS）有效，安全和生活质量（QOL）（QOL）：FOENIX-CCA2

Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

著录项

引文网络

相似文献

相关主题

期刊订阅